|
1
|
McGlynn KA and London WT: The global
epidemiology of hepatocellular carcinoma: Present and future. Clin
Liver Dis. 15:223–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Seraq HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoeman AD, Al-Chalabi T, Karani JB,
Quaglia A, Devlin J, Mieli-Vergani G, Bomford A, O'Grady JG,
Harrison PM and Heneghan MA: Evaluation of risk factors in the
development of hepatocellular carcinoma in autoimmune hepatitis:
Implications for follow-up and screening. Hepatology. 48:863–870.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang W, He H, Zang M, Wu Q, Zhao H, Lu
LL, Ma P, Zheng H, Wang N, Zhang Y, et al: Genetic features of
aflatoxin-associated hepatocellular carcinoma. Gastroenterology.
153:249–262.e2. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Altekruse SF, Henley SJ, Cucinelli JE and
McGlynn KA: Changing hepatocellular carcinoma incidence and liver
cancer mortality rates in the United States. Am J Gastroenterol.
109:542–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim SR, Kudo M, Hino O, Han KH, Chung YH
and Lee HS; Organizing Committee of Japan-Korea Liver Symposium, :
Epidemiology of hepatocellular carcinoma in Japan and Korea. A
review. Oncology. 75 (Suppl 1):S13–S16. 2008. View Article : Google Scholar
|
|
8
|
Murakami T, Kim T, Oi H, Nakamura H,
Igurashi H, Matsushita M, Okamura J and Kozuka T: Detectability of
hypervascular hepatocellular carcinoma by arterial phase images of
MR and spiral CT. Acta Radiol. 36:372–376. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park SJ, Jang JY, Jeong SW, Cho YK, Lee
SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, et al: Usefulness of
AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing
hepatocellular carcinoma. Medicine (Baltimore). 96:e58112017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tomimaru Y, Eguchi H, Nagano H, Wada H,
Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I,
Umeshita K, et al: Circulating microRNA-21 as a novel biomarker for
hepatocellular carcinoma. J Hepatol. 56:167–175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carleton M, Cleary MA and Linsley PS:
MicroRNAs and cell cycle regulation. Cell Cycle. 6:2127–2132. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harfe BD: MicroRNAs in vertebrate
development. Curr Opin Genet Dev. 15:410–415. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garzon R, Calin GA and Croce CM: MicroRNA
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Melo SA and Esteller M: Dysregulation of
microRNAs in cancer: Playing with fire. FEBS Lett. 585:2087–2099.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Osaki M, Takeshita F and Ochiya T:
MicroRNAs as biomarkers and therapeutic drugs in human cancer.
Biomarkers. 13:658–670. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Budhu A, Jia HL, Forgues M, Liu CG,
Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, et al:
Identification of metastasis-related microRNAs in hepatocellular
carcinoma. Hepatology. 47:897–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morishita A, Iwama H, Fujihara S, Sakamoto
T, Fujita K, Tani J, Miyoshi H, Yoneyama H, Himoto T and Masaki T:
MicroRNA profiles in various hepatocellular carcinoma cell lines.
Oncol Lett. 12:1687–1692. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morishita A and Masaki T: MicroRNAs as
possible biomarkers for hepatocellular carcinoma. Hepatol Res.
48:499–501. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gibbings DJ, Ciaudo C, Erhardt M and
Voinnet O: Multivesicular bodies associate with components of miRNA
effector complexes and modulate miRNA activity. Nat Cell Biol.
11:1143–1149. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yin C, Zhou X, Yan J and Zhang G:
Potential role of circulating miR-21 in the diagnosis and prognosis
of digestive system cancer: A systematic review and meta-analysis.
Medicine (Baltimore). 94:e21232015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liver Cancer Study Group of Japan. In, .
General rules for the clinical and pathological study of primary
liver cancer. 3rd. Tokyo, Kanehara: 2010
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Ogata-Kagata H, Izumiya M, Kurioka D,
Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Soneda H,
et al: Circulating exosomal microRNAs as biomarkers of colon
cancer. PLoS One. 9:e929212014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Que R, Ding G, Chen J and Cao L: Analysis
of serum exosomal microRNAs and clinicopathologic features of
patients with pancreatic adenocarcinoma. World J Surg Oncol.
11:2192013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Taylor DD and Gercel-Talor C: MicroRNA
signatures of tumor-derived exosomes as diagnostic biomarkers of
ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang J, Zhou Y, Lu J, Sun Y, Xiao H, Liu M
and Taian L: Combined detection of serum exosomal miR-21 and HOTAIR
as diagnostic and prognostic biomarkers for laryngeal squamous cell
carcinoma. Med Oncol. 31:1482014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang H, Hou L, Li A, Duan Y, Gao H and
Song X: Expression of serum exosomal microRNA-21 in human
hepatocellular carcinoma. Biomed Res Int.
2014:8648942014.PubMed/NCBI
|
|
31
|
Sugimachi K, Matsumura T, Hirata H, Uchi
R, Ueda M, Ueo H, Shinden Y, Iguchi H, Eguchi H, Shirabe K, et al:
Identification of a bona fide microRNA biomarker in serum exosomes
that predicts hepatocellular carcinoma recurrence after liver
transplantation. Br J Cancer. 112:532–538. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Gao JS, Tang X, Tucker LD,
Quesenberry P, Rigoutsos I and Ramratnam B: MicroRNA 125a and its
regulation of the p53 tumor suppressor gene. FEBS Lett.
583:3725–3730. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu S, Huang S, Ding J, Zhao Y, Liang L,
Liu T, Zhan R and He X: Multiple microRNAs modulate p21Cip1/Waf1
expression by directly targeting its 3′ untranslated region.
Oncogene. 29:2302–2308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Scott GK, Goga A, Bhaumik D, Berger CE,
Sullivan CS and Benz CC: Coordinate suppression of ERBB2 and ERBB3
by enforced expression of micro-RNA miR-125a or miR-125b. J Biol
Chem. 282:1479–1486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tang H, Li RP, Liang P, Zhou YL and Wang
GW: miR-125a inhibits the migration and invasion of liver cancer
cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol
Lett. 10:681–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li G, Zhang W, Gong L and Huang X:
MicroRNA-125a-5p inhibits cell proliferation and induces apoptosis
in hepatitis B virus-related hepatocellular carcinoma by
downregulation of ErbB3. Oncol Res. 27:449–458. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
O'Day E and Lal A: MicroRNAs and their
target gene in breast cancer. Breast Cancer Res. 12:2012010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang G, Mao W, Zheng S and Ye J: Epidermal
growth factor receptor-regulated miR-125a-5p-a metastatic inhibitor
of lung cancer. FEBS J. 276:5571–5578. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nishida N, Mimori K, Fabbri M, Yokobori T,
Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y and Mori M:
MicroRNA-125a-5p is an independent prognostic factor in gastric
cancer and inhibits the proliferation of human gastric cancer cells
in combination with Trastuzumab. Clin Cancer Res. 17:2725–2733.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li W, Xie L, He X, Li J, Tu K, Wei L, Wu
J, Guo Y, Ma X, Zhang P, et al: Diagnostic and prognostic
implications of microRNAs in human hepatocellular carcinoma. Int J
Cancer. 123:1616–1622. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bi Q, Tang S, Xia L, Du R, Fan R, Gao L,
Jin J, Liang S, Chen Z, Xu G, et al: Ectopic expression of miR-125a
inhibits the proliferation and metastasis of hepatocellular
carcinoma by targeting MMP11 and VEGF. PLoS One. 7:e401692012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Potenza N, Papa U, Mosca N, Zerbini F,
Nobile V and Rosso A: Human microRNA hsa-miR-125a-5p interferes
with expression of hepatitis B virus surface antigen. Nucleic Acid
Res. 39:5157–5163. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Coppola N, Potenza N, Pisaturo M, Mosca N,
Tonziello G, Signoriello G, Messina V, Sagnelli C, Russo A and
Sagnelli E: Liver microRNA hsa-miR-125a-5p in HBV chronic
infection: Correlation with HBV replication and disease
progression. PLoS One. 8:e653362013. View Article : Google Scholar : PubMed/NCBI
|
